Alnylam slashes staff by 33% as only two lead RNAi programmes remain in house
This article was originally published in Scrip
Executive Summary
Alnylam Pharmaceuticals, a pioneer in RNA interference ("gene silencing") said on 20 January that it is cutting about a third of its workforce as its realigns its resources to focus on a narrower internal pipeline – one that it had outlined to investors on 8 January.